Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The initiative is part of a broader campaign to ensure a healthy and stigma-free working environment within the justice ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which is viewed as a key part of the drugmaker's growth strategy in HIV. The ...

Calgary-based virtual pharmacy PurposeMed is completing its U.S. expansion this month, bringing its popular Freddie service ...

Cheap generic versions of a groundbreaking HIV-prevention jab should be available in more than 100 countries from 2027, ...

Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral ...

Patients who achieved HIV virologic suppression tended to be older and were more likely to report continued engagement in HIV care than those with persistent viremia.

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Learn about the unique health and social needs of HIV-infected senior Americans. Health experts emphasize the importance of prevention, testing, and care.

New study findings could change treatments for HIV in young children. HIV remission may be possible for very young children ...

Generic versions of a groundbreaking injectable HIV-prevention drug should be available for $40 a year in more than 100 ...

Gilead's groundbreaking HIV prevention drug will soon be available at a fraction of its U.S. price in over 100 countries, ...